< -5%

-5% to -3%

-3% to 0%

Venkys

Ovobel Foods

Essex Marine

0% to 3%

Uniroyal Marine

Simran Farms

3% to 5%

Hyundai launches Prime Taxi range for commercial mobility in India, Prime HB and Prime SD offer petrol+CNG engines, starting at Rs 5.99 lakh, Special warranty, flexible finance, high fuel efficiency target fleet operators

* Hyundai launches Prime Taxi range for commercial mobility in India
* Prime HB and Prime SD offer petrol+CNG engines, starting at Rs 5.99 lakh
* Special warranty, flexible finance, high fuel efficiency target fleet operators

Hyundai Motor India launched the Prime Taxi range, entering the commercial mobility segment with Prime HB and Prime SD models. Aimed at fleet operators, these petrol+CNG vehicles offer low ownership costs, extended warranties, and flexible financing options.

shorts/business/hyundai-motor-india-enters-commercial-mobility-launches-prime-hatchback-sedan-prices-start-at-rs-5-99-lakh

* Hyundai launches Prime Taxi range for commercial mobility in India
* Prime HB and Prime SD offer petrol+CNG engines, starting at Rs 5.99 lakh
* Special warranty, flexible finance, high fuel efficiency target fleet operators

Hyundai Motor India on Tuesday announced its entry into the commercial mobility segment with the launch of its dedicated taxi offerings under the 'Prime Taxi' range.

Purpose-built to address the evolving needs of fleet operators and taxi entrepreneurs, the Prime range -- Prime HB (hatchback) and Prime SD (sedan) -- offer reliability, low cost of ownership and superior comfort with strong earning potential, Hyundai Motor India Ltd (HMIL) said in a statement.

"Fleet operators and taxi drivers look for vehicles that deliver maximum uptime, predictable maintenance and low operating costs, and the Hyundai Prime range has been developed precisely with these priorities in mind," HMIL Managing Director &amp; CEO designate, Tarun Garg said.

Both Prime HB and Prime SD are available with 1.2-litre Kappa 4-cylinder engine (Petrol + CNG) and the models are offered at starting prices of Rs 5,99,900 for Prime HB and Rs 6,89,900 for Prime SD (ex-showroom).

Flexible finance solutions with repayment tenure of up to 72 months further enhance accessibility for first-time and expanding fleet operators, HMIL added.

Both models come with special extended warranty packages of 4th and 5th year / 180,000 KMs (whichsoever earlier) for high running vehicles, ensuring predictable maintenance and lower total cost of ownership (at 47 paise / km). Flexible finance solutions with repayment tenure of up to 72 months further enhance accessibility for first-time and expanding fleet operators. The Prime range benefits from Hyundai’s wide nationwide sales and service network, ensuring maximum uptime, faster service turnaround and complete peace of mind - critical factors for commercial customers whose livelihoods depend on vehicle availability. Exclusive trained fleet care advisor (FCA) would be available to attend taxi and fleet customers at the Hyundai dealerships, the company said.

The new commercial vehicles are designed to deliver exceptional performance, while offering superior ride and comfort to both the driver as well as passengers. With a strong emphasis on operational costs, the Hyundai Prime range offers exceptional fuel efficiency - 28.40 km/kg for Prime SD and 27.32 km/kg for Prime HB6. The new affordable offerings aim to empower taxi operators with dependable vehicles that maximize their operations and income, it added.

Shares of <a href="https://www.moneycontrol.com/india/stockpricequote/automobile-passenger-cars/hyundaimotorindia/HMI01">Hyundai Motor India Ltd</a> settled lower at Rs 2,300.9 per share on the NSE, down 0.88 percent.

<em><strong>Disclaimer:</strong> The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

Ownership, Material Conflicts of Interest and Disciplinary History

MCD is a wholly owned subsidiary of Network 18 Media & Investments Ltd ("Network18"), in which Independent Media Trust (IMT) holds 56.89% stake. Reliance Industries Limited ("RIL") is the sole beneficiary of IMT. Network18 and RIL and their subsidiaries, joint ventures and associates can be considered as associates of MCD.

Details of Associate

Receipt of Compensation

Third-Party Compensation

Employment History

Market-Making Activities

Use of Artificial Intelligence

Hyundai Motor India enters commercial mobility, launches Prime hatchback, sedan; prices start at Rs 5.99 lakh

Hyundai Motor India on Tuesday announced its entry into the commercial mobility segment with the launch of its dedicated taxi offerings under the 'Prime Taxi' range.

Purpose-built to address the evolving needs of fleet operators and taxi entrepreneurs, the Prime range -- Prime HB (hatchback) and Prime SD (sedan) -- offer reliability, low cost of ownership and superior comfort with strong earning potential, Hyundai Motor India Ltd (HMIL) said in a statement.

&quot;Fleet operators and taxi drivers look for vehicles that deliver maximum uptime, predictable maintenance and low operating costs, and the Hyundai Prime range has been developed precisely with these priorities in mind,&quot; HMIL Managing Director &amp;amp; CEO designate, Tarun Garg said.

Both Prime HB and Prime SD are available with 1.2-litre Kappa 4-cylinder engine (Petrol + CNG) and the models are offered at starting prices of Rs 5,99,900 for Prime HB and Rs 6,89,900 for Prime SD (ex-showroom).

Flexible finance solutions with repayment tenure of up to 72 months further enhance accessibility for first-time and expanding fleet operators, HMIL added.

Both models come with special extended warranty packages of 4th and 5th year / 180,000 KMs (whichsoever earlier) for high running vehicles, ensuring predictable maintenance and lower total cost of ownership (at 47 paise / km). Flexible finance solutions with repayment tenure of up to 72 months further enhance accessibility for first-time and expanding fleet operators. The Prime range benefits from Hyundai’s wide nationwide sales and service network, ensuring maximum uptime, faster service turnaround and complete peace of mind - critical factors for commercial customers whose livelihoods depend on vehicle availability. Exclusive trained fleet care advisor (FCA) would be available to attend taxi and fleet customers at the Hyundai dealerships, the company said.

The new commercial vehicles are designed to deliver exceptional performance, while offering superior ride and comfort to both the driver as well as passengers. With a strong emphasis on operational costs, the Hyundai Prime range offers exceptional fuel efficiency - 28.40 km/kg for Prime SD and 27.32 km/kg for Prime HB6. The new affordable offerings aim to empower taxi operators with dependable vehicles that maximize their operations and income, it added.

Shares of Hyundai Motor India Ltd settled lower at Rs 2,300.9 per share on the NSE, down 0.88 percent.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

Ajanta Pharma shares rose after Motilal Oswal predicted gains from new drug., Ajanta to source semaglutide from Biocon, targeting Asia and Africa markets, Motilal Oswal maintains "buy" rating with a target price of Rs 3,145

* Ajanta Pharma shares rose after Motilal Oswal predicted gains from new drug.
* Ajanta to source semaglutide from Biocon, targeting Asia and Africa markets
* Motilal Oswal maintains "buy" rating with a target price of Rs 3,145

Ajanta Pharma shares rose after Motilal Oswal highlighted strong prospects from its new weight-loss drug semaglutide, sourced via Biocon. The brokerage expects significant sales growth, high margins, and reiterated a “buy” rating with a Rs 3,145 target.

shorts/business/ajanta-pharma-rises-3-5-as-motilal-oswal-expects-strong-gains-from-new-weight-loss-drug-sees-up-to-17-upside

* Ajanta Pharma shares rose after Motilal Oswal predicted gains from new drug.
* Ajanta to source semaglutide from Biocon, targeting Asia and Africa markets
* Motilal Oswal maintains "buy" rating with a target price of Rs 3,145

<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/ajantapharma/AP22">Ajanta Pharma</a> shares settled higher on Tuesday after domestic brokerage Motilal Oswal said the company could see strong gains from its new weight-loss drug.

The stock settled at Rs 2,715 apiece on the NSE, up 0.92 percent. During the day, it touched a high of Rs 2,784.80, up 3.52 percent. The scrip has risen for the last two trading sessions.

Motilal Oswal said Ajanta Pharma’s partnership with Biocon to source the weight-loss drug semaglutide is a meaningful step towards introducing newer therapies and securing market share.

The brokerage estimates potential annualised sales from semaglutide in Asia and Africa at USD 25–30 million from the second half of FY28, with EBITDA margins of 50–55 percent.

It expects Ajanta Pharma’s overall revenue and profit to grow at a compound annual growth rate of 11 percent and 16 percent, respectively, over FY26–28.

Motilal Oswal reiterated its “buy” rating on the stock and maintained a target price of Rs 3,145, implying an upside of about 17 percent.

The company’s surplus cash position provides enough cushion to acquire products that complement its branded generics portfolio. In fact, the company has meaningfully scaled its acquired brands over the past 12 months, the brokerage said.

In emerging markets, AJP is pursuing an asset-light, marketing-led model and will source semaglutide from Biocon under an in-licensing arrangement. The company has exclusive or semi-exclusive marketing rights across 23 countries in Africa and three countries in the Middle East and Central Asia. With patents expiring in Mar’26 and approvals expected between late 2026 and early 2027, this structure enables AJP to capture upside without assuming manufacturing risk, it added.

<em><strong>Disclaimer:</strong> The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

Ajanta Pharma rises 3.5% as Motilal Oswal expects strong gains from new weight-loss drug, sees up to 17% upside

Ajanta Pharma shares settled higher on Tuesday after domestic brokerage Motilal Oswal said the company could see strong gains from its new weight-loss drug.

The stock settled at Rs 2,715 apiece on the NSE, up 0.92 percent. During the day, it touched a high of Rs 2,784.80, up 3.52 percent. The scrip has risen for the last two trading sessions.

Motilal Oswal said Ajanta Pharma’s partnership with Biocon to source the weight-loss drug semaglutide is a meaningful step towards introducing newer therapies and securing market share.

The brokerage estimates potential annualised sales from semaglutide in Asia and Africa at USD 25–30 million from the second half of FY28, with EBITDA margins of 50–55 percent.

It expects Ajanta Pharma’s overall revenue and profit to grow at a compound annual growth rate of 11 percent and 16 percent, respectively, over FY26–28.

Motilal Oswal reiterated its “buy” rating on the stock and maintained a target price of Rs 3,145, implying an upside of about 17 percent.

The company’s surplus cash position provides enough cushion to acquire products that complement its branded generics portfolio. In fact, the company has meaningfully scaled its acquired brands over the past 12 months, the brokerage said.

In emerging markets, AJP is pursuing an asset-light, marketing-led model and will source semaglutide from Biocon under an in-licensing arrangement. The company has exclusive or semi-exclusive marketing rights across 23 countries in Africa and three countries in the Middle East and Central Asia. With patents expiring in Mar’26 and approvals expected between late 2026 and early 2027, this structure enables AJP to capture upside without assuming manufacturing risk, it added.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

Auto stocks rose on hopes of strong December sales data, Maruti Suzuki hit an all-time high, Strong IIP data also boosted auto sector shares

* Auto stocks rose on hopes of strong December sales data
* Maruti Suzuki hit an all-time high
* Strong IIP data also boosted auto sector shares

Auto stocks rose on December 30, lifting the Nifty Auto index over 1%, as hopes for strong December sales and robust industrial production data boosted sentiment. Maruti Suzuki hit a record high, while Hero MotoCorp, Ashok Leyland, and Bajaj Auto gained over 2%.

shorts/business/maruti-suzuki-shares-hit-fresh-lifetime-high-auto-stocks-rise-ahead-of-monthly-auto-sales-data

* Auto stocks rose on hopes of strong December sales data
* Maruti Suzuki hit an all-time high
* Strong IIP data also boosted auto sector shares

The shares of automakers rose in trade on December 30 amid rising hopes for strong auto sales data for the month of December.

The sharp rise in the share prices pushed the <a href="https://www.moneycontrol.com/indian-indices/nifty-auto-52.html">Nifty Auto index</a> up more than 1 percent to end the session at 27,889.65 and snap a three-session losing streak, with heavyweight <a href="https://www.moneycontrol.com/india/stockpricequote/auto-carsjeeps/marutisuzukiindia/MS24">Maruti Suzuki</a> shares hitting a fresh all-time high.
<h3><strong>Hopes for strong December auto sales data:</strong></h3>
Analysts expect the automakers to post strong auto sales for the month of December. Nuvama Wealth Management said that these firms will continue to benefit from lower GST, which has led to better demand, Informist reported.

The brokerage expects double-digit year-on-year growth in sales volumes across categories for the month, it added.

"Sales volumes are likely to be driven by continued positive customer sentiments spurred by better affordability (courtesy GST cuts), new products, interest rate cuts and adequate finance availability despite some pressure on rural sentiments due to a drop in retail crop prices…Furthermore, we reckon exports shall rise in double digits led by growth in Asia, Africa, and Latin America," the domestic brokerage further said, as quoted by Informist.

"The auto sales numbers expected in two days will give an indication of the sustainability of the consumption boom in the economy. This is significant from the economic growth perspective, too," said VK Vijayakumar, Chief Investment Strategist, Geojit Investments.
<h3><strong>Strong IIP data:</strong></h3>
The rise in the auto stocks may have also bee driven by <a href="https://www.moneycontrol.com/news/business/economy/industrial-output-rebounds-to-over-two-year-high-of-6-7-in-november-13746973.html">strong IIP numbers</a>. India’s industrial production rebounded sharply in November, with the Index of Industrial Production (IIP) rising 6.7 percent—a 25-month high—from just 0.5 percent in October, data released on December 29 showed.

The recovery was broad-based, with strong improvement across all three major sectors. Manufacturing, which accounts for over 75 percent of the index, accelerated to an over two-year high of 8 percent, up from 2 percent in the previous month, providing the biggest boost to headline growth.

"Sector-wise, while auto stocks gained on robust IIP data," said Vinod Nair, Head of Research, Geojit Investments.
<h3><strong>Top gainers on the auto index:</strong></h3>
<a href="https://www.moneycontrol.com/india/stockpricequote/auto-23-wheelers/heromotocorp/HHM">Hero MotoCorp</a> shares emerged as the top gainer on the index, jumping more than 2 percent to snap a three-session gaining streak. Ashok Leyland and <a href="https://www.moneycontrol.com/india/stockpricequote/auto-23-wheelers/bajajauto/BA10">Bajaj Auto</a> shares also jumped more than 2 percent each, while Mahindra &amp; Mahindra (<a href="https://www.moneycontrol.com/india/stockpricequote/auto-carsjeeps/mahindramahindra/MM">M&amp;M</a>) and TVS Motor Company shares gained nearly 2 percent each.

Bharat Forge and <a href="https://www.moneycontrol.com/india/stockpricequote/auto-lcvshcvs/tatamotorspassengervehicles/TM03">Tata Motors Passenger Vehicles</a> shares rose nearly 1 percent each. Maruti Suzuki shares gained nearly 2 percent earlier during the day to hit a fresh all-time high of Rs 16,818 apiece, before paring some gains to close 0.5 percent higher at Rs 16,625 apiece.

Sona BLW Precision Forgings, Bosch and UNO Minda shares closed in the green with marginal gains. Bucking the trend, Royal Enfield-maker <a href="https://www.moneycontrol.com/india/stockpricequote/auto-lcvshcvs/eichermotors/EM">Eicher Motors</a>, Exide Industries and Tube Investments of India shares fell more than 1 percent each.

<a href="https://www.moneycontrol.com/india/stockpricequote/auto-ancillaries-auto-truckmotorcycle-parts/samvardhanamothersoninternational/MSS01">Samvardhana Motherson International</a> shares also closed in the red with marginal losses.

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

Maruti Suzuki shares hit fresh lifetime high, auto stocks rise ahead of monthly auto sales data

The shares of automakers rose in trade on December 30 amid rising hopes for strong auto sales data for the month of December.

The sharp rise in the share prices pushed the Nifty Auto index up more than 1 percent to end the session at 27,889.65 and snap a three-session losing streak, with heavyweight Maruti Suzuki shares hitting a fresh all-time high.
Hopes for strong December auto sales data:
Analysts expect the automakers to post strong auto sales for the month of December. Nuvama Wealth Management said that these firms will continue to benefit from lower GST, which has led to better demand, Informist reported.

The brokerage expects double-digit year-on-year growth in sales volumes across categories for the month, it added.

&quot;Sales volumes are likely to be driven by continued positive customer sentiments spurred by better affordability (courtesy GST cuts), new products, interest rate cuts and adequate finance availability despite some pressure on rural sentiments due to a drop in retail crop prices…Furthermore, we reckon exports shall rise in double digits led by growth in Asia, Africa, and Latin America,&quot; the domestic brokerage further said, as quoted by Informist.

&quot;The auto sales numbers expected in two days will give an indication of the sustainability of the consumption boom in the economy. This is significant from the economic growth perspective, too,&quot; said VK Vijayakumar, Chief Investment Strategist, Geojit Investments.
Strong IIP data:
The rise in the auto stocks may have also bee driven by strong IIP numbers. India’s industrial production rebounded sharply in November, with the Index of Industrial Production (IIP) rising 6.7 percent—a 25-month high—from just 0.5 percent in October, data released on December 29 showed.

The recovery was broad-based, with strong improvement across all three major sectors. Manufacturing, which accounts for over 75 percent of the index, accelerated to an over two-year high of 8 percent, up from 2 percent in the previous month, providing the biggest boost to headline growth.

&quot;Sector-wise, while auto stocks gained on robust IIP data,&quot; said Vinod Nair, Head of Research, Geojit Investments.
Top gainers on the auto index:
Hero MotoCorp shares emerged as the top gainer on the index, jumping more than 2 percent to snap a three-session gaining streak. Ashok Leyland and Bajaj Auto shares also jumped more than 2 percent each, while Mahindra &amp;amp; Mahindra (M&amp;amp;M) and TVS Motor Company shares gained nearly 2 percent each.

Bharat Forge and Tata Motors Passenger Vehicles shares rose nearly 1 percent each. Maruti Suzuki shares gained nearly 2 percent earlier during the day to hit a fresh all-time high of Rs 16,818 apiece, before paring some gains to close 0.5 percent higher at Rs 16,625 apiece.

Sona BLW Precision Forgings, Bosch and UNO Minda shares closed in the green with marginal gains. Bucking the trend, Royal Enfield-maker Eicher Motors, Exide Industries and Tube Investments of India shares fell more than 1 percent each.

Samvardhana Motherson International shares also closed in the red with marginal losses.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

PVR Inox shares drop 2% after Ajay Bijli pledges 4 lakh shares, Ajay Bijli's pledged shares total 29.44 lakh, 3% of share capital, PVR Inox shares fell 9% in the past month and 24% in 2025 to date.

* PVR Inox shares drop 2% after Ajay Bijli pledges 4 lakh shares
* Ajay Bijli's pledged shares total 29.44 lakh, 3% of share capital
* PVR Inox shares fell 9% in the past month and 24% in 2025 to date.

PVR Inox shares fell over 2% after promoter and MD Ajay Bijli pledged about 4 lakh shares for personal borrowing, bringing his total pledged shares to 29.44 lakh, or 3% of company capital. The stock is down over 24% in 2025 so far.

shorts/business/pvr-inox-shares-fall-2-after-promoter-ajay-bijli-pledges-4-lakh-shares

* PVR Inox shares drop 2% after Ajay Bijli pledges 4 lakh shares
* Ajay Bijli's pledged shares total 29.44 lakh, 3% of share capital
* PVR Inox shares fell 9% in the past month and 24% in 2025 to date.

The shares of <a href="https://www.moneycontrol.com/india/stockpricequote/mediaentertainment/pvrinox/PVR">PVR Inox</a> dropped more than 2 percent on December 30 after the company announced that its promoter and managing director Ajay Bijli pledged around 4 lakh shares of the company for personal borrowing.

The shares of the theatre chain closed at Rs 996 apiece on Tuesday, the lowest level seen by the stock in nearly five months.
<h3><strong>PVR Inox promoter pledges shares:</strong></h3>
In an exchange filing released on December 29, PVR Inox announced that Bijli has pledged 3.10 lakh shares to Infina Finance Private Limited, and 90,037 shares to HSBC InvestDirect Financial Services. This has taken the total number of shares pledged by Ajay Bijli to 29.44 lakh shares, or 3 percent of the company’s total share capital.
<h3><strong>What is share pledging?</strong></h3>
Share pledge refers to the practice where promoters of a company use their shares as collateral to secure loans from financial institutions. This is typically done when promoters need money but do not wish to sell their shares. By pledging shares, they can raise funds without diluting their equity holding in the company.

Bijli's pledges were created on December 24 for "personal borrowing". Ajay Bijli held 5.5 percent stake in the company, as at the end of the April-June quarter of the ongoing financial year.
<h3><strong>PVR Inox share price:</strong></h3>
PVR Inox shares have fallen nearly 4 percent in the past five days, and over 9 percent in the past one month. The stock rose over 2.5 percent in the past six months, but is down over 24 percent in 2025 so far.

Earlier this month, the stock saw a brief surge as Ranveer Singh-starrer Dhurandhar created new box office records. However, the stock then failed to hold on to the momentum.

Follow all <a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-flat-start-us-asian-markets-fall-3-liveblog-13747857.html">LIVE updates</a> from the stock markets here.

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

PVR Inox shares fall 2% after promoter Ajay Bijli pledges 4 lakh shares

The shares of PVR Inox dropped more than 2 percent on December 30 after the company announced that its promoter and managing director Ajay Bijli pledged around 4 lakh shares of the company for personal borrowing.

The shares of the theatre chain closed at Rs 996 apiece on Tuesday, the lowest level seen by the stock in nearly five months.
PVR Inox promoter pledges shares:
In an exchange filing released on December 29, PVR Inox announced that Bijli has pledged 3.10 lakh shares to Infina Finance Private Limited, and 90,037 shares to HSBC InvestDirect Financial Services. This has taken the total number of shares pledged by Ajay Bijli to 29.44 lakh shares, or 3 percent of the company’s total share capital.
What is share pledging?
Share pledge refers to the practice where promoters of a company use their shares as collateral to secure loans from financial institutions. This is typically done when promoters need money but do not wish to sell their shares. By pledging shares, they can raise funds without diluting their equity holding in the company.

Bijli's pledges were created on December 24 for &quot;personal borrowing&quot;. Ajay Bijli held 5.5 percent stake in the company, as at the end of the April-June quarter of the ongoing financial year.
PVR Inox share price:
PVR Inox shares have fallen nearly 4 percent in the past five days, and over 9 percent in the past one month. The stock rose over 2.5 percent in the past six months, but is down over 24 percent in 2025 so far.

Earlier this month, the stock saw a brief surge as Ranveer Singh-starrer Dhurandhar created new box office records. However, the stock then failed to hold on to the momentum.

Follow all LIVE updates from the stock markets here.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

* Mangalam Drugs shares surge as Vijay Kedia's firm buys Rs 33 lakh stake.
* Stock rose 5 percent, extending gains for second straight session
* Shares have dropped 78 percent in 2025 despite recent surge

Mangalam Drugs shares hit upper circuit, rising 5% after Vijay Kedia's firm bought over Rs 33 lakh stake at a discount. Despite recent gains, the stock is down 78% in 2025 and 82% from its 52-week high, with a market cap near Rs 42 crore.

shorts/business/mangalam-drugs-shares-hit-5-upper-circuit-after-vijay-kedia-buys-stake-worth-rs-33-lakh

The shares of <a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/mangalamdrugsorganics/MDO">Mangalam Drugs and Organics</a> jumped 5 percent to hit the upper circuit after ace investor Vijay Kedia's office bought stake worth more than Rs 33 lakh in the firm.

The shares of the company remained locked in the upper circuit at Rs 26.20 apiece, extending gains for the second consecutive session.
<h3><strong>Vijay Kedia buys stake in Mangalam Drugs:</strong></h3>
According to data on NSE, Kedia Securities Private Limited on December 29 bought around 1.38 lakh shares at a price of Rs 24.15 per share in a bulk deal. This takes the total transaction value to Rs 33.28 lakh.

The price at which the firm bought shares of the company marks a 3 percent discount to the previous closing price of Rs 24.96 per share.

Mangalam Drugs and Organics manufactures Active Pharmaceutical Ingredients (APIs) and intermediates.
<h3><strong>Mangalam Drugs share price:</strong></h3>
Mangalam Drugs shares have seen a sharp rise recently, jumping nearly 10 percent in the past five days. The stock has however fallen around 68 percent in the past six months, and is down more than 78 percent in 2025 so far.

After hitting a 52-week high of Rs 124.89 apiece on January 1 this year, the stock tumbled 82 percent to hit a fresh 52-week low of Rs 22.8 apiece yesterday. It currently has a market capitalisation of nearly Rs 42 crore.

Follow all <a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-updates-gift-nifty-indicates-a-flat-start-us-asian-markets-fall-3-liveblog-13747857.html">LIVE updates</a> from the stock markets here.

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

Mangalam Drugs shares hit 5% upper circuit after Vijay Kedia buys stake worth Rs 33 lakh

The shares of Mangalam Drugs and Organics jumped 5 percent to hit the upper circuit after ace investor Vijay Kedia's office bought stake worth more than Rs 33 lakh in the firm.

The shares of the company remained locked in the upper circuit at Rs 26.20 apiece, extending gains for the second consecutive session.
Vijay Kedia buys stake in Mangalam Drugs:
According to data on NSE, Kedia Securities Private Limited on December 29 bought around 1.38 lakh shares at a price of Rs 24.15 per share in a bulk deal. This takes the total transaction value to Rs 33.28 lakh.

The price at which the firm bought shares of the company marks a 3 percent discount to the previous closing price of Rs 24.96 per share.

Mangalam Drugs and Organics manufactures Active Pharmaceutical Ingredients (APIs) and intermediates.
Mangalam Drugs share price:
Mangalam Drugs shares have seen a sharp rise recently, jumping nearly 10 percent in the past five days. The stock has however fallen around 68 percent in the past six months, and is down more than 78 percent in 2025 so far.

After hitting a 52-week high of Rs 124.89 apiece on January 1 this year, the stock tumbled 82 percent to hit a fresh 52-week low of Rs 22.8 apiece yesterday. It currently has a market capitalisation of nearly Rs 42 crore.

Follow all LIVE updates from the stock markets here.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

Fish/Poultry & Meat Products Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Fish/Poultry & Meat Products industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

Hyundai Motor India enters commercial mobility, launches Prime hatchback, sedan; prices start at Rs 5.99 lakh

Ajanta Pharma rises 3.5% as Motilal Oswal expects strong gains from new weight-loss drug, sees up to 17% upside

Maruti Suzuki shares hit fresh lifetime high, auto stocks rise ahead of monthly auto sales data

PVR Inox shares fall 2% after promoter Ajay Bijli pledges 4 lakh shares

Mangalam Drugs shares hit 5% upper circuit after Vijay Kedia buys stake worth Rs 33 lakh

Fish/Poultry & Meat Products Industry StocksCheck latest stock performance, list of stocks, earnings review & more details about the Fish/Poultry & Meat Products industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

Hyundai Motor India enters commercial mobility, launches Prime hatchback, sedan; prices start at Rs 5.99 lakh

Ajanta Pharma rises 3.5% as Motilal Oswal expects strong gains from new weight-loss drug, sees up to 17% upside

Maruti Suzuki shares hit fresh lifetime high, auto stocks rise ahead of monthly auto sales data

PVR Inox shares fall 2% after promoter Ajay Bijli pledges 4 lakh shares

Mangalam Drugs shares hit 5% upper circuit after Vijay Kedia buys stake worth Rs 33 lakh

Fish/Poultry & Meat Products Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Fish/Poultry & Meat Products industry stocks.